IPP Bureau
Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr
By IPP Bureau - May 18, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
By IPP Bureau - May 18, 2025
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital
By IPP Bureau - May 18, 2025
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Sun Pharma gets FDA approval for new device to treat skin disease
By IPP Bureau - May 18, 2025
Punita Lal Joins Lupin Board as Additional Director
By IPP Bureau - May 18, 2025
She has held senior positions at Coca-Cola in China and PepsiCo in India
Lupin receives USFDA approval for Rivaroxaban Tablets
By IPP Bureau - May 18, 2025
Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr
By IPP Bureau - May 18, 2025
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr
By IPP Bureau - May 18, 2025
The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025
Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr
By IPP Bureau - May 18, 2025
The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025
Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr
By IPP Bureau - May 18, 2025
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr
By IPP Bureau - May 17, 2025
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr
By IPP Bureau - May 17, 2025
Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
By IPP Bureau - May 16, 2025
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Shelter Pharma launches three new products
By IPP Bureau - May 16, 2025
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
